Developer docs
API playgroundTry for free, no card

Search company profiles

Volumetric

Full company profile

uuid000358r

Namestring
Volumetric
Legal namestring
Volumetric Biotechnologies
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Volumetric is an advanced biomaterials and biofabrication company headquartered in Houston, Texas. Founded in 2018, it built a portfolio of proprietary bioprinting materials — including LAP Photoinitiator, 3400 Da and 6000 Da PEGDA powders, and GelMA — that serve researchers and organizations developing vascularized human tissues and bioprinted constructs. The materials are supplied as sterile-filtered aqueous solutions and lyophilized powders suitable for photocurable bioprinting workflows.

In the fall of 2021, Volumetric was acquired by 3D Systems, and its team and technology became the foundation for 3D Systems' bioprinting facility in Houston. Post-acquisition, the materials portfolio is commercialized through 3D Systems' global catalog and channels rather than as standalone Volumetric SKUs. Pre-acquisition, the company had raised approximately $1.83 million in disclosed funding, participated in Y Combinator, and operated with 1-10 employees — indicating an R&D-stage venture whose commercial revenue depended on parent-company distribution.

The business model is fundamentally a materials IP and platform play: value is created through proprietary photocurable biomaterial formulations that integrate into 3D Systems' bioprinting systems and broader healthcare 3D printing portfolio. Customer concentration is institutional — targeting academic and commercial tissue-engineering programs and, post-integration, 3D Systems' existing medical-device, dental, and healthcare customer base — with go-to-market occurring through direct enterprise sales channels and the parent's established catalog infrastructure.

Short descriptiontext

Volumetric is a Houston-based biomaterials and biofabrication company developing proprietary photocurable bioprinting materials (LAP, PEGDA, GelMA) for vascularized human tissue research. Founded in 2018, it was acquired by 3D Systems in fall 2021.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioprinting materials, biomaterials manufacturing, tissue engineering, biofabrication chemicals, 3D bioprinting supplies
Industry1 code
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Bioprinting Materials
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Modular Housing Sales
TypeOne Time License
Description

VBC generates revenue through the sale of factory-manufactured modular housing units to government entities and developers. The company competes for municipal contracts and large-scale housing development projects.

inquirer.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Volumetric Biotechnologies
Description

Bioprinting technology division acquired by 3D Systems, focused on vascularized human tissues and bioprinted constructs.

3dsystems.com
Core offering1 text field

Volumetric develops and supplies specialty biomaterials used in bioprinting and tissue engineering. Its portfolio includes photoinitiators (LAP), PEGDA polymers of varying molecular weights, and GelMA hydrogels that enable researchers to fabricate vascularized human tissues and bioprinted constructs. Following its acquisition by 3D Systems in fall 2021, the company's materials are now offered as part of 3D Systems' bioprinting materials catalog.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Volumetric Biotechnologies, acquired by 3D Systems in fall 2021, operates as an acquired brand focused on bioprinting technology. The company serves as the foundation for 3D Systems' bioprinting facility in Houston, Texas, developing vascularized human tissues and bioprinted constructs. The product portfolio consists of bioprinting materials including LAP Photoinitiator, 3400 Da PEGDA powder, 6000 Da PEGDA powder, and GelMA (coming soon) — all offered as part of the 3D Systems materials catalog.

Product and service4 records
1LAP Photoinitiator
CategoryBioprinting material
Description

Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) Photoinitiator provided as a sterile-filtered aqueous solution for bioprinting applications; sold as part of the Volumetric team materials portfolio within 3D Systems.

23400 Da Poly(ethylene glycol) (PEGDA)
CategoryBioprinting material
Description

3400 Da Poly(ethylene glycol) diacrylate (PEGDA) powder used as a biomaterial for bioprinting applications.

36000 Da Poly(ethylene glycol) (PEGDA)
CategoryBioprinting material
Description

6000 Da Poly(ethylene glycol) diacrylate (PEGDA) powder used as a biomaterial for bioprinting applications.

4GelMA
CategoryBioprinting material
Description

Gelatin methacryloyl (GelMA) provided as a sterile-filtered aqueous solution for bioprinting applications. Currently listed as coming soon.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-13
Description

Philadelphia Mayor Cherelle L. Parker has proposed $10 million in her budget to attract a modular housing factory to the city. VBC responded to the city's Request for Information for modular housing factory development. This represents a potential major strategic partnership to establish manufacturing operations in Philadelphia.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Poietis is a French bioprinting company developing laser-assisted bioprinting for tissue engineering and regenerative medicine, with overlapping technology and customer focus though a narrower product line.

TypeDirect peer
Description

Allevi was a bioprinting startup (bioprinters and bioinks) acquired by 3D Systems in 2021 alongside Volumetric; it is a direct predecessor peer, operating in the same bioprinting hardware and materials category.

TypeDirect peer
Description

regenHU is a Swiss bioprinting systems and bioink manufacturer with a comparable product mix of bioprinters and biomaterial consumables targeting research and translational tissue engineering applications.

TypeBroad incumbent
Description

3D Systems is the parent of Volumetric Biotechnologies and a broad 3D printing incumbent whose healthcare/bioprinting division now houses the Volumetric technology — relevant as the parent platform and channel for Volumetric's materials.

TypeEmerging player
Description

Tissue Regeneration Systems develops 3D-printed biodegradable scaffolds for bone and tissue regeneration; an emerging player in 3D-printed regenerative medicine with a more application-narrow focus than Volumetric.

TypeDirect peer
Description

BICO, parent of CELLINK, is the most direct competitor to Volumetric: a bioprinting platform company offering both bioprinters and a broad portfolio of bioinks (GelMA, PEG-based, collagen) and tissue culture consumables serving the same research customer base.

TypeDirect peer
Description

Organovo is a pioneering 3D bioprinting company focused on generating functional human tissues for research and therapeutic applications, directly comparable to Volumetric's vascularized tissue engineering focus.

8Aspect Biosystems
TypeDirect peer
Description

Aspect Biosystems develops microfluidic 3D bioprinting platforms and bioink materials for tissue engineering, operating in the same bioprinting/biomaterials category as Volumetric with overlapping customer segments in pharma and academic research.

TypeDirect peer
Description

CollPlant develops recombinant human collagen and bioinks for 3D bioprinting of tissues and organs, directly comparable to Volumetric's biomaterials portfolio and its role as a consumables supplier in bioprinting workflows.

TypeBroad incumbent
Description

Stratasys is a broad 3D printing incumbent with healthcare and materials adjacencies; relevant as a peer in the parent-company category and a potential competitor in healthcare 3D printing materials and services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Volumetric

Bioprinting Materialsvolumetricbio.com

Volumetric is a Houston-based biomaterials and biofabrication company developing proprietary photocurable bioprinting materials (LAP, PEGDA, GelMA) for vascularized human tissue research. Founded in 2018, it was acquired by 3D Systems in fall 2021.

What Volumetric does

Volumetric is an advanced biomaterials and biofabrication company headquartered in Houston, Texas. Founded in 2018, it built a portfolio of proprietary bioprinting materials — including LAP Photoinitiator, 3400 Da and 6000 Da PEGDA powders, and GelMA — that serve researchers and organizations developing vascularized human tissues and bioprinted constructs. The materials are supplied as sterile-filtered aqueous solutions and lyophilized powders suitable for photocurable bioprinting workflows.

In the fall of 2021, Volumetric was acquired by 3D Systems, and its team and technology became the foundation for 3D Systems' bioprinting facility in Houston. Post-acquisition, the materials portfolio is commercialized through 3D Systems' global catalog and channels rather than as standalone Volumetric SKUs. Pre-acquisition, the company had raised approximately $1.83 million in disclosed funding, participated in Y Combinator, and operated with 1-10 employees — indicating an R&D-stage venture whose commercial revenue depended on parent-company distribution.

The business model is fundamentally a materials IP and platform play: value is created through proprietary photocurable biomaterial formulations that integrate into 3D Systems' bioprinting systems and broader healthcare 3D printing portfolio. Customer concentration is institutional — targeting academic and commercial tissue-engineering programs and, post-integration, 3D Systems' existing medical-device, dental, and healthcare customer base — with go-to-market occurring through direct enterprise sales channels and the parent's established catalog infrastructure.

Volumetric firmographics

Firmographics
Name
Volumetric
Legal name
Volumetric Biotechnologies
Website
https://volumetricbio.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Volumetric is a Houston-based biomaterials and biofabrication company developing proprietary photocurable bioprinting materials (LAP, PEGDA, GelMA) for vascularized human tissue research. Founded in 2018, it was acquired by 3D Systems in fall 2021.
Ownership category
akta.pro rank

Volumetric industry classification

Industry
Product category
Bioprinting Materials
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Bioprinting materials
  • Biomaterials manufacturing
  • Tissue engineering
  • Biofabrication chemicals
  • 3D bioprinting supplies

Where Volumetric is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Volumetric business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations

Revenue model

  1. Modular Housing Sales: VBC generates revenue through the sale of factory-manufactured modular housing units to government entities and developers. The company competes for municipal contracts and large-scale housing development projects.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Volumetric product offering

Product offering

Core offering

Volumetric develops and supplies specialty biomaterials used in bioprinting and tissue engineering. Its portfolio includes photoinitiators (LAP), PEGDA polymers of varying molecular weights, and GelMA hydrogels that enable researchers to fabricate vascularized human tissues and bioprinted constructs. Following its acquisition by 3D Systems in fall 2021, the company's materials are now offered as part of 3D Systems' bioprinting materials catalog.

Product overview

Volumetric Biotechnologies, acquired by 3D Systems in fall 2021, operates as an acquired brand focused on bioprinting technology. The company serves as the foundation for 3D Systems' bioprinting facility in Houston, Texas, developing vascularized human tissues and bioprinted constructs. The product portfolio consists of bioprinting materials including LAP Photoinitiator, 3400 Da PEGDA powder, 6000 Da PEGDA powder, and GelMA (coming soon) — all offered as part of the 3D Systems materials catalog.

Differentiator

Problem solved

Functional benefit

Brands

  • Volumetric Biotechnologies: Bioprinting technology division acquired by 3D Systems, focused on vascularized human tissues and bioprinted constructs.

Products and services

  • LAP Photoinitiator Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) Photoinitiator provided as a sterile-filtered aqueous solution for bioprinting applications; sold as part of the Volumetric team materials portfolio within 3D Systems.
  • 3400 Da Poly(ethylene glycol) (PEGDA) 3400 Da Poly(ethylene glycol) diacrylate (PEGDA) powder used as a biomaterial for bioprinting applications.
  • 6000 Da Poly(ethylene glycol) (PEGDA) 6000 Da Poly(ethylene glycol) diacrylate (PEGDA) powder used as a biomaterial for bioprinting applications.
  • GelMA Gelatin methacryloyl (GelMA) provided as a sterile-filtered aqueous solution for bioprinting applications. Currently listed as coming soon.

Companies that use Volumetric

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Volumetric technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Volumetric partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • City of PhiladelphiacoreStrategic or Co-development Partner · 13 March 2026Philadelphia Mayor Cherelle L. Parker has proposed $10 million in her budget to attract a modular housing factory to the city. VBC responded to the city's Request for Information for modular housing factory development. This represents a potential major strategic partnership to establish manufacturing operations in Philadelphia.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Volumetric competitors and assessment

Company assessment

Emerging players

  • Poietis: Poietis is a French bioprinting company developing laser-assisted bioprinting for tissue engineering and regenerative medicine, with overlapping technology and customer focus though a narrower product line.
  • Tissue Regeneration Systems: Tissue Regeneration Systems develops 3D-printed biodegradable scaffolds for bone and tissue regeneration; an emerging player in 3D-printed regenerative medicine with a more application-narrow focus than Volumetric.

Direct peers

  • Allevi (acquired by 3D Systems): Allevi was a bioprinting startup (bioprinters and bioinks) acquired by 3D Systems in 2021 alongside Volumetric; it is a direct predecessor peer, operating in the same bioprinting hardware and materials category.
  • regenHU: regenHU is a Swiss bioprinting systems and bioink manufacturer with a comparable product mix of bioprinters and biomaterial consumables targeting research and translational tissue engineering applications.
  • BICO (CELLINK): BICO, parent of CELLINK, is the most direct competitor to Volumetric: a bioprinting platform company offering both bioprinters and a broad portfolio of bioinks (GelMA, PEG-based, collagen) and tissue culture consumables serving the same research customer base.
  • Organovo Holdings: Organovo is a pioneering 3D bioprinting company focused on generating functional human tissues for research and therapeutic applications, directly comparable to Volumetric's vascularized tissue engineering focus.
  • Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting platforms and bioink materials for tissue engineering, operating in the same bioprinting/biomaterials category as Volumetric with overlapping customer segments in pharma and academic research.
  • CollPlant Biotechnologies: CollPlant develops recombinant human collagen and bioinks for 3D bioprinting of tissues and organs, directly comparable to Volumetric's biomaterials portfolio and its role as a consumables supplier in bioprinting workflows.

Broad incumbents

  • 3D Systems Corporation: 3D Systems is the parent of Volumetric Biotechnologies and a broad 3D printing incumbent whose healthcare/bioprinting division now houses the Volumetric technology — relevant as the parent platform and channel for Volumetric's materials.
  • Stratasys: Stratasys is a broad 3D printing incumbent with healthcare and materials adjacencies; relevant as a peer in the parent-company category and a potential competitor in healthcare 3D printing materials and services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Volumetric social profiles

Digital presence

Volumetric financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Volumetric leadership team

Management profile

Number of profiles

Profiles1 record

Volumetric funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Volumetric M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Volumetric

What does Volumetric do?

Volumetric develops and supplies specialty biomaterials used in bioprinting and tissue engineering. Its portfolio includes photoinitiators (LAP), PEGDA polymers of varying molecular weights, and GelMA hydrogels that enable researchers to fabricate vascularized human tissues and bioprinted constructs. Following its acquisition by 3D Systems in fall 2021, the company's materials are now offered as part of 3D Systems' bioprinting materials catalog.

Is Volumetric a public or private company?

Volumetric is a private company. It is classified as corporate owned and is currently acquired.

When was Volumetric founded?

Volumetric was founded in 2018. It employs 11 to 50 people.

Where is Volumetric based?

Volumetric is headquartered in Houston, United States, in the North America region.

How does Volumetric make money?

One revenue line is on record: modular Housing Sales.

Who are Volumetric's main competitors?

Emerging players on record are Poietis and Tissue Regeneration Systems. Direct peers are Allevi (acquired by 3D Systems), regenHU, BICO (CELLINK), Organovo Holdings, Aspect Biosystems and CollPlant Biotechnologies. Broad incumbents are 3D Systems Corporation and Stratasys.

Does Volumetric have an API?

No public API is recorded for Volumetric.

What industry is Volumetric in?

Volumetric's product category is Bioprinting Materials. Its primary akta.pro industry code is HLAAAGAC, 3D Bioprinting & Biofabrication. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Philadelphia InquirerMayor Parker wants $10 million to bring a factory that manufactures housing to PhillyPhiladelphia Mayor Cherelle L. Parker has proposed $10 million in her budget to attract a modular housing factory to the city, aiming to address the housing crisis while creating union jobs. The proposal follows the city's Request for Information for modular housing factory development, to which Philadelphia-based Volumetric Building Cos. (VBC) and companies from outside the region responded. However, VBC's CEO warns that a Philadelphia factory would face higher operating costs due to local business taxes and would need a steady supply of work to compete with Pennsylvania's 27 existing modular housing factories in lower-cost areas.GlobeNewswire3D Systems Reports Third Quarter 2021 Financial Results3D Systems reported Q3 2021 revenue of $156.1 million, up 14.6% year-over-year and 35.9% adjusted for divestitures. Adjusted EBITDA margin was 10.5% and diluted EPS was $2.34. The company closed Oqton and anticipates closing Volumetric Biotechnologies in Q4 2021.BioSpaceVolumetric to Be Acquired by 3D Systems to Advance Tissue and Organ ManufacturingVolumetric, a Houston biofabrication start-up, agreed to be acquired by 3D Systems in a deal with a $45 million closing payment and up to $355 million in milestone earnouts. The acquisition will establish a 20,000 sq. ft. facility in Houston's East End Maker Hub, building on a partnership with United Therapeutics for bioprinted human organs.GlobeNewswire3D Systems Announces Acquisition of Volumetric Biotechnologies3D Systems acquired Houston-based Volumetric Biotechnologies, a bioprinting company focused on human organ manufacturing. The deal includes a $45 million closing payment and up to $355 million more, totaling $400 million if milestones are met. The transaction is expected to close in the fourth quarter.3D Systems3D Systems Announces Acquisition of Volumetric Biotechnologies3D Systems announced on October 27, 2021 that it is acquiring Houston-based biotech Volumetric, co-founded by Drs. Jordan Miller and Bagrat Grigoryan, which develops bioprinted human organs. The deal is a $45 million closing payment plus up to $355 million in milestones, for a possible $400 million total, roughly half cash and half stock, expected to close in the fourth quarter.GlobeNewswire3D Systems Announces Acquisition of Volumetric Biotechnologies3D Systems announced the acquisition of Volumetric Biotechnologies, a Houston-based biotech firm specializing in human organ bioprinting, for a total potential value of $400 million. This transaction aims to expand 3D Systems' capabilities in regenerative medicine by integrating Volumetric's expertise to accelerate the development of vascularized human tissues and organs. The deal is expected to close in the fourth quarter of 2021.Mpo-mag3D Systems to Acquire Biofabrication Startup Volumetric3D Systems has agreed to acquire biofabrication startup Volumetric in a deal valued at up to $400 million, comprising a $45 million closing payment and potential milestone earnouts. The acquisition integrates Volumetric into 3D Systems' joint development program with United Therapeutics Corporation to advance the bioprinting of human organs. The combined team will establish a new facility in Houston to continue research on regenerative medicine therapies.Business Wire BlogVolumetric to Be Acquired by 3D Systems to Advance Tissue and Organ Manufacturing3D Systems has agreed to acquire Houston-based biofabrication startup Volumetric in a deal valued at up to $400 million, comprising a $45 million closing payment and $355 million in milestone earnouts. This acquisition integrates Volumetric's 3D bioprinting technology with 3D Systems' existing partnership with United Therapeutics to advance the manufacturing of human organs for regenerative medicine.TechCrunch3D-printing organs moves a few more steps closer to commercializationPrellis Biologics secured $8.7 million in funding and announced successful implantation of 3D-printed vascularized tumors in animal subjects, accelerating its timeline toward commercializing vascular tissue structures for drug discovery and organ transplants. Concurrently, Volumetric Bio unveiled progress on a bioprinting technology that mimics lung air sacs using food dye-based photoreactors to create complex multivascular networks.